April 30, 2018 07:08 AM EDT
Deals

Unit­ed Ther­a­peu­tics bags ri­val SteadyMed for a bar­gain base­ment deal worth up to $216M, elim­i­nat­ing patent threat

John Carroll

Editor & Founder

Unit­ed Ther­a­peu­tics $UTHR CEO Mar­tine Roth­blatt won’t be look­ing over her shoul­ders as a po­ten­tial ri­val to Unit­ed’s lead drug makes its way through an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

A service from the Financial Times